Question special
Trainee ST 4-8

Working in a publicly-funded health service, I would like to know of any cost-benefit analysis of Nirsevimab vs our current use of Palivizumab. If this is not available yet, are you able to tell us when/ how this data will become available to us? And if you are proposing a broadening of the categories of infants who receive RSV prophylaxis, would you do a separate cost-benefit analysis for eg. healthy term infants?